These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36804617)

  • 1. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
    Dessources K; Ferrando L; Zhou QC; Iasonos A; Abu-Rustum NR; Reis-Filho JS; Riaz N; Zamarin D; Weigelt B
    Gynecol Oncol; 2023 Apr; 171():15-22. PubMed ID: 36804617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer.
    Jiang F; Jiang S; Cao D; Mao M; Xiang Y
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
    Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
    Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
    Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
    Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability.
    Risinger JI; Chandramouli GV; Maxwell GL; Litzi T; Berchuck A; Umar A
    Cancer Biomark; 2006; 2(1-2):61-8. PubMed ID: 17192060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
    Li BL; Wan XP
    J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.
    Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN
    J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
    Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
    Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
    Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
    JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.
    Talhouk A; Derocher H; Schmidt P; Leung S; Milne K; Gilks CB; Anglesio MS; Nelson BH; McAlpine JN
    Clin Cancer Res; 2019 Apr; 25(8):2537-2548. PubMed ID: 30523022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
    Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
    Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations and gene amplification in endometrial cancer.
    Praiss AM; Marra A; Zhou Q; Rios-Doria E; Momeni-Boroujeni A; Iasonos A; Selenica P; Brown DN; Aghajanian C; Abu-Rustum NR; Ellenson LH; Weigelt B
    Gynecol Oncol; 2023 Dec; 179():16-23. PubMed ID: 37890416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the prognostic immune subtype in copy-number high endometrial cancer.
    Mao M; Jiang F; Han R; Xiang Y
    J Gynecol Oncol; 2024 Jan; 35(1):e8. PubMed ID: 37857563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
    Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
    Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
    Lai J; Xu T; Yang H
    BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers.
    Ni Y; Soliman A; Joehlin-Price A; Abdul-Karim F; Rose PG; Mahdi H
    Immunotherapy; 2021 Oct; 13(14):1179-1192. PubMed ID: 34424031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.